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STATEMENT OF TRANSLATIONAL RELEVANCE: 
The detection of changes in tumor glucose metabolism, tumor diameter or tumor volume within 
a few weeks of commencing treatment has the potential to inform stratification of patient 
management. For patients with recurrent ovarian cancer, there is an urgent need to identify 
more effective therapies, and an imaging tool that can robustly identify early response would be 
of value both in the clinical setting and as a biomarker for drug development.  Validation of 
imaging biomarkers is critical for effective and reliable use in clinical trials.  Test/re-test data for 
measurements of FDG uptake, tumor diameter and tumor volume are essential in order to 
determine repeatability coefficients, thereby allowing the confident use of these techniques.  
However, these data have not previously been established for ovarian cancer.  This study 
establishes robust repeatability coefficients for FDG measurements, enabling evidence-based 
use of PET/CT in stratification of patients into those with a metabolic or volumetric response to 
treatment. 
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ABSTRACT 
Purpose:   
Repeatability of baseline FDG-PET/CT measurements has not been tested in ovarian cancer. 
This dual-center, prospective study assessed variation in tumor FDG uptake, tumor diameter 
(TD) and tumor volume (TV) from sequential FDG-PET/CT and contrast-enhanced CT (CECT) 
in patients with recurrent platinum-sensitive ovarian cancer.  
Methods:   
Patients underwent two pre-treatment baseline FDG-PET/CT (n=21) and CECT (n=20) at 2 
clinical sites with different PET/CT instruments. Patients were included if they had at least one 
target lesion (TL) in the abdomen with an SUV maximum (SUVmax) of ≥2.5 and a long axis 
diameter of ≥15mm. Two independent reading methods were used to evaluate repeatability of 
TD and SUV uptake: on site and at an imaging clinical research organization (CRO). TV reads 
were only performed by CRO. In each reading set, TLs were independently measured on 
sequential imaging.  
Results:   
Median time between FDG-PET/CT was 2 days (range 1-7). For site reads, concordance 
correlation coefficient (CCC) for SUVmean, SUVmax and TD were 0.95, 0.94 and 0.99 
respectively. Repeatability coefficients were 16.3%, 17.3% and 8.8% for SUVmean, SUVmax 
and TD respectively. Similar results were observed for CRO reads. TV CCC was 0.99 with a 
repeatability coefficient of 28.1%.  
Conclusions: 
There was excellent test/retest repeatability for FDG-PET/CT quantitative measurements across 
two sites and two independent reading methods. Cut-off values for determining change in 
SUVmean, SUVmax and TV establish limits to determine metabolic and/or volumetric response 
to treatment in platinum-sensitive relapsed ovarian cancer.  
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BACKGROUND  
Epithelial ovarian cancer (EOC) remains the most lethal gynecological malignancy and overall 
survival has not changed significantly over the past 15 years (1). Most patients present with 
advanced stage disease and the primary treatment modality is surgical cytoreduction followed 
by platinum/taxane-based chemotherapy. Relapsed disease is classified by its likely response 
to further treatment with platinum-based chemotherapy, being either platinum-sensitive or 
platinum resistant (2). However, the majority of patients eventually develop progressive 
platinum-resistance. There is a clear unmet clinical need to identify new treatments for women 
with ovarian cancer.   
Evaluation of the effectiveness of new drug treatments in EOC depends upon assessment of 
response and progression-free survival. Objective response measurement using RECIST 1.1 
criteria (uni-dimensional tumor diameter) is highly validated across many cancer types, as well 
as having high utility in clinical practice (3;4). However, it is used inconsistently by regulatory 
authorities for the purposes of drug registration (5).  There are inherent limitations using uni-
dimensional measurements. Notably, the time taken for tumor shrinkage of 30% is typically in 
excess of 9 weeks and inevitably delays treatment decisions; particularly in ovarian cancer the 
shape of the mass may alter during treatment so that the long axis does not reflect change in 
volume and residual soft tissue along peritoneal or serosal surfaces or in complex masses may 
be difficult to measure and quantify or may not represent active disease (6-8). Despite these 
recognized limitations, contrast enhanced CT (CECT) is currently the standard of care 
technique for monitoring response to treatment in ovarian cancer, together with the serum 
cancer antigen 125 (CA 125) level. Conversely,  individual patients with EOC would benefit from 
the development of more sensitive methods for determining non-responders. Earlier diagnoses 
of non-response or progressive disease will spare patients from the toxicities associated with 
futile treatments and access alternative therapies sooner.   
FDG-PET/CT has been proposed as an imaging tool for the detection of response, by 
demonstrating metabolic changes in the tumor, early in the course of treatment (9;10). Early 
metabolic changes may also have prognostic value. In ovarian cancer, Avril et al found that in 
the neo-adjuvant setting, by using an a priori stated cut-off value for decrease of standardized 
uptake value (SUV) from baseline of 20% after the first cycle, median overall survival was 38.3 
months in metabolic responders compared with 23.1 months in metabolic non-responders (11). 
There was a significant correlation between FDG-PET metabolic response after the first 
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(p=0.008) and third (p=0.005) cycles of chemotherapy and overall survival. Importantly, 
standard clinical response criteria did not correlate with overall survival, suggesting that FDG-
PET response may be a more powerful prognostic tool.  
However, in order to adopt FDG-PET response into both clinical practice and drug-
development, the range of variability (or confidence interval) surrounding the measurement of 
the standardized uptake value (SUV) of FDG tumor uptake must be determined, in order to be 
able to set appropriate cut-off values for identifying true responses in tumor tissue. The 
repeatability of tumor FDG uptake in lung and other solid organ tumors have recently been 
evaluated in a meta-analysis (12). However, FDG avid lesions in the abdomen and pelvis are 
often difficult to delineate and no test retest data regarding FDG uptake or tumor volume data 
have been published for EOC. More importantly, no previous study has compared the test retest 
variation in tumor FDG uptake with test retest variation in tumor volumes determined in 
combination with CECT. Repeatability data would allow the determination of robust cut-off 
values for defining metabolic response or metabolic progression in the absence of either 
complete disappearance of all lesions or appearance of one or more new lesions.  Without this 
information, changes in SUV may be erroneously interpreted as response or progression and 
this could adversely affect patient care and clinical trial outcome. Also, although there is a 
general assumption that anatomical changes occur after several cycles of chemotherapy, there 
is little information available about early changes in tumor volumes and their ability to predict 
treatment response early during chemotherapy.  
The purpose of this study was to establish the variation in the measurements of FDG uptake 
and tumor volumes in recurrent ovarian cancer. Our aims were to measure prospectively the 
test-retest repeatability of quantitative PET measurements (SUVmean, SUVmax) using a 
standardized volume of interest as well as tumor diameter and tumor volume in a cohort of 
women with recurrent ovarian cancer treated at 2 sites using different PET/CT instruments.     
PATIENTS AND METHODS 
The  study  protocol  was  reviewed  and  approved  by  Cambridgeshire  2  Research  Ethics 
Committee, UK (09/H0308/129).  Patients were recruited by two academic oncology centers in 
the UK  from  a  larger  study  cohort  evaluating  treatment  response. All  patients  gave written 
informed  consent.  All  screened  patients  had  platinum‐sensitive  (defined  as  platinum‐free 
interval of  at  least  6 months) ovarian  cancer  that had  relapsed  as  confirmed by  findings on 
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computed  tomography  (CT), with or without  an elevated CA‐125  level. The patient  inclusion 
and exclusion criteria are  listed  in appendix 1. Of the cohort of 43 patients recruited  into the 
main study, 21 patients agreed  to  take part  in the  test‐retest sub‐study. Center 1 recruited 8 
patients and center 2 recruited 13 patients, mean age 60.4 years (median 61 years, range 38 to 
74). Patients underwent two identical baseline imaging investigations prior to starting standard 
of  care  platinum‐based  chemotherapy.  This study was performed according to the latest 
guidelines and recommendations from the MHRA and FDA for clinical trials as a prospective 
dual center study. All data we collected at the time of origin and collected in a secure database. 
The trial was funded and monitored by Merck and Co, which enabled us to conduct the study on 
the highest level of evidence possible.  
 
Imaging techniques 
Following enrolment, a baseline FDG-PET/CT scan was performed, immediately followed by a 
contrast-enhanced CT scan (CECT).  This was termed baseline 1 (BL1).  Patients who did not 
have at least one lesion with both, an SUVmax ≥ 2.5 at BL1 FDG-PET scan and a longest 
diameter lesion of ≥1.5 cm on the BL1 CECT scan were discontinued on the study. In those 
patients with at least one such lesion, imaging was repeated 1 - 7 days later (baseline 2 - BL2) 
prior to starting treatment.  
FDG-PET imaging  
Patients were imaged using a Gemini TF with a 64 channel CT (Philips Healthcare UK) in center 
1 and a GE Discovery 690 (GE Healthcare UK) at center 2. Both PET/CT scanners were 
comparable in performance and both used time-of-flight technology. Both sites were qualified by 
the CRO (Perceptives Informatics, Billerica, MA, USA) and by the UK National Cancer 
Research Institute programme for PET sites involved in multi-centre trials. Daily quality control 
and regular standard calibration procedures were undertaken. The same PET/CT scanner was 
used for each patient throughout the study. All patients underwent the entire PET/CT imaging 
procedure twice within 7 days without any therapeutic interventions in-between.  
Blood glucose levels were measured prior to the administration of the radiotracer (within 1 hour) 
for BL1 and BL2. Patients with a blood glucose level exceeding 150 mg/dL (8.3 mmol/L) were 
not injected with the radiotracer.  The mean blood glucose level was 5.75mmol/l.  The mean 
difference between BL1 and BL2 was 0.6 mmol/l, median 0.3 mmol/l and range 0 – 2.7 mmol/l.  
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The net dose of FDG injected was measured by placing the injection syringe in a dose calibrator 
before and after administration, with decay corrections factored into the calculation. All FDG 
doses were injected through a venous catheter. Patients rested for approximately 50 minutes in 
a comfortable recliner after FDG injection prior to PET/CT imaging. Patients were then asked to 
empty their bladder and positioned in prone on the scanner table. A scout scan was obtained to 
plan the imaging procedure. A transmission CT scan for attenuation correction was performed 
prior to the PET emission scan (at about 55 minutes post injection of FDG). PET emission 
scans started at 60 minutes (median = 60, mean = 61.4, range = 59 – 70 minutes) post-
injection. If the 60-minute FDG uptake time target was missed, subsequent studies aimed for 
the actual uptake period at the first baseline FDG-PET/CT.  The difference in FDG uptake time 
between the test and retest PET scans was between 0 to 3 minutes in all but three patients (in 
whom there was a difference of 6, 7 and 10 minutes respectively), with a mean difference of 1.9 
minutes and median of 1 minute.  The duration of all emission scans were identical for each 
PET/CT scanner.  The acquisition parameters are given in appendix 2.  
Contrast-enhanced CT 
The CECT scan was performed directly following the baseline FDG-PET/CT scan including the 
abdomen and pelvis (and chest if clinically indicated). CECT was defined as a volumetric CT 
acquisition of the body using a multidetector spiral CT scanner in the portal venous phase 
following intravenous contrast administration (CECT acquisition parameters are available in 
supplementary table 2). Images were viewed on 5mm reformatted slices in the axial plane, as 
per RECIST 1.1 rules, with the option to view in reformatted sagittal or coronal planes. All target 
lesions were measured in the axial plane (the plane of acquisition). The CECT scans were of 
sufficient quality to enhance interpretation of FDG-PET scans, permit RECIST assessments, 
and enable tumor volume image analysis to be performed. For all CECT scans, intravenous 
iodinated contrast media were used according to local standards of care.  If contrast media was 
contraindicated in a patient, then CECT scan was not performed and the test-retest 
measurements for RECIST and volumetric analysis could not be evaluated.   
Image analysis 
Measurement of SUV 
FDG uptake in tumor lesions was quantitatively assessed using Standardized Uptake Values 
(SUV) as a measure for tumor glucose metabolism. Activity concentrations in the attenuation-
corrected PET images were converted to SUV’s by dividing the activity concentrations derived 
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from PET by the decay-corrected injected dose divided by the patient’s body weight. The 
following SUV parameters were obtained within a volume of interest: maximum SUV (SUVmax), 
mean SUV (SUVmean) and the mean weighted SUV, which is defined as the sum of all counts 
in all of the volumes of interest (VOIs) representing all of the TLs divided by the sum of all the 
voxels in all of the VOIs representing the TLs (the SUV mean weighted average, SUVmwa).  
Image reads 
Analysis of the FDG-PET scan and the CECT was performed without knowledge of any specific 
clinical information apart from the inclusion and exclusion criteria. Two independent reads of the 
FDG-PET and CECT were made, one being a site read and the other an imaging CRO read, 
using two different methods. The reads were performed to reflect the practice of trial reporting 
whereby once targets have been chosen on the first baseline scan, measurements of the same 
targets are subsequently performed. Target selection was independent between site and CRO 
as two different reading methods were being evaluated for test retest repeatability.  
Site reads 
The baseline FDG-PET/CT and CECT were viewed simultaneously by the PET expert and the 
gynecologic oncology CT expert respectively. A maximum of 5 target lesions were selected from 
the CECT, maximum two per organ. Although the inclusion criteria required at least one lesion 
to be SUVmax ≥2.5 and diameter ≥15mm, the criteria used for selecting other target lesions 
were that each target lesion was FDG avid and of minimal size criteria as defined by RECIST 
1.1 (10mm long axis for non-nodal target and 15mm short axis for nodal target).   
The longest diameter of each TL was then measured on the CECT according to RECIST rules. 
On the FDG-PET images, a spherical VOI with a diameter of 15mm was used to measure the 
SUVmean and SUVmax of each target, following manual identification of the most avid part of 
the tumor lesion. All measured parameters were recorded and screen shots of each selected 
target lesion were stored. The BL1 scan was then closed. The BL2 scan was then opened and 
each target lesion was measured using to the same technique.   Each target lesion was 
checked with BL1 to ensure that the same target lesions were used, but with blinding to the prior 
measurements.  
Contract Research Organisation reads  
CRO reads for SUV measurements and TD were considered the secondary reads. CECT 
volumes and FDG-PET images were read by a single independent radiologist with significant 
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experience in reading CT-volumes and FDG-PET.  CECT images were assessed for target 
lesion diameter and volume. The CT lesion selection criteria followed the guidelines set forth by 
the RECIST allowing selection of up to 10 lesions ≥10mm to be selected with a maximum of 5 
per organ. The FDG-PET images for this study were used to assess the SUVmax and SUVmwa 
for up to 10 lesions.  As long as appropriate, the same target lesions were chosen on PET and 
CECT. However, when an FDG-avid lesion was not suitable for RECIST measurements or vice 
versa, measurements on the other modality were not enforced. Thirty-five percent of subjects 
had different numbers of targets in the two modalities (28% had additional FDG-PET targets, 
7% had additional CECT targets). All but one PET avid target had an SUVmax ≥2.5. CECT 
images were used to delineate the target lesions which were described as series of Regions of 
Interest (ROIs), drawn on each slice where present, to ensure the entire volume of the lesion 
was assessed (VOI). ROIs were created using a semiautomatic approach combining freehand 
and autosegmentation, which allowed adjustment by a radiologist. The ROIs for target lesions 
provided longest diameter for non-nodal lesions, longest short axis diameter for nodal lesion 
and volume assessment of the individual target lesions.  The lesion locations from CECT 
images were used to follow consistently the target lesions on sequential imaging.   FDG-PET 
images were viewed along with the CECT images to confirm the selection of the same lesion 
selected on CECT, up to the extent possible to meet lesion selection criteria. Metabolic volumes 
were determined by an isocontour of 25% of the SUVmax. 
Statistical methods  
Repeatability 
When the number of target lesions increases, the sum of target lesions (in terms of SUV and 
tumor size) also increases.  As a result, correlation between repeated scans may be inflated 
due to different numbers of target lesions across patients.  Therefore, for repeatability 
assessment, the average was used to summarize measures across multiple target lesions 
within a scan.  
The repeatability of SUV and tumor size measurements was assessed based on the two 
baseline scans.  The Kendall tau and Shapiro-Wilk tests were performed on both original and 
log-transformed data and the log-transformed data were closer to normality and constant 
variance.  Scatter plots (Scan 1 vs Scan 2) with a 45° line through the origin and Bland-Altman 
plots (difference vs mean) were generated.  Concordance correlation coefficient (CCC), within 
subject standard deviation (SD), and within-subject coefficient of variation (CV) were derived. 
The difference between two baseline measurements for the same patient was considered to be 
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within the normal variation for 95% of pairs of observations. The repeatability coefficient was 
estimated to be twice the standard deviation of the paired differences. On a logarithmic scale, 
expressed as a percent change from baseline, the repeatability coefficient was [1 – exp (-2 * 
SDdiff)]  x 100%. 
RESULTS 
21 patients underwent two baseline imaging studies. In one case, the diagnostic CECT 
component could not be done with intravenous contrast media on BL2, and therefore the CT 
components (TD and TV) were not evaluated for repeatability, with a final number of 20 patients 
evaluable for TD and TV.  The number of target lesions in each data set is provided in table 1. 
For the primary site reads, the mean diameter of target lesions was 32mm and all target lesions 
were > 15mm except for 4 which were between 11.1 and 14.6mm.  
Median time between sequential FDG-PET/CT was 2 days (range 1 to 7, mean 2.4 days). The 
repeatability of SUV and tumor size measurements were plotted in Figures 1 – 4. The paired 
values from the same subject fell near the solid line. The Pearson correlation between 
SUVmean and SUVmax was 0.95 for the site read. Concordance correlation coefficient (CCC) 
and repeatability cut-off values are given in table 2.  Concordance correlation coefficient (and 
80% confidence intervals) for SUVmean (average), SUVmax (average) and TD (average) were 
0.95 (0.92-0.98), 0.94 (0.90- 0.97) and 0.99 (0.98 – 1.00) respectively. Repeatability cut-off 
values (indicating the lower limit of the 95% CI for % change between two baseline scans) were 
16.3% for SUVmean (average), 17.3% for SUVmax (average) and 8.8% for TD (average). The 
repeatability results from the two reading methods were similar. Tumor volume (average) CCC 
was 0.99 (0.98 – 1.00) with a repeatability cut-off value of 28.1%.  
The repeatability results are plotted in figures 1- 4.  
DISCUSSION 
FDG-PET is increasingly being used as a biomarker for treatment monitoring in cancer patients 
(13-15). In order to identify a metabolic response it is necessary to establish the normal 
variation of tumor FDG uptake prior to therapeutic intervention. We found a high test-retest 
repeatability of quantitative measures of tumor glucose metabolism (FDG uptake) using different 
parameters derived from Standardized Uptake Values (SUV) in ovarian cancer. This is in line 
with previous reports who observed a good repeatability of FDG uptake measurements in other 
tumors, as reported in a recent meta-analysis (12). The first study addressing this issue dates 
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back in 1999 and included 16 patients with different tumor types who underwent FDG-PET 
within 10 days without anti-cancer treatment in-between (16). In that study, the differences of 
repeated measurements were approximately normally distributed for all SUV parameters with a 
SD of the mean percentage difference of about 10%. The authors concluded that changes of a 
SUV parameter outside the 95% normal range may be used to define a metabolic response to 
therapy. 
The PET technology has advanced since then from stand-alone PET scanners to combined 
PET-CT and subsequent studies have shown a high repeatability for measuring tumor FDG 
uptake using FDG-PET/CT in a limited number of patients (17;18). This is the first study to 
address this issue in ovarian cancer. The abdomen is particularly difficult to quantitatively 
evaluate for tumor FDG uptake due to physiologic excretion of FDG via the urinary tract and due 
to variable physiologic FDG uptake within bowel structures. Ovarian cancer often presents with 
serosal implants, which can be subject to motion, potentially compromising longitudinal FDG-
PET imaging for treatment monitoring. To date, only few studies have addressed FDG-PET 
treatment monitoring in ovarian cancer. Our study is of potentially high clinical relevance as we 
showed that changes beyond 15-20% in tumor glucose metabolism allows the identification of 
treatment induced changes, which provides the basis for future prospective treatment 
monitoring studies in ovarian cancer. There are a number of targeted therapies currently in 
development or already being evaluated clinically. This includes drugs targeting the PI3K – Akt- 
mTOR pathway, the inhibition of angiogenesis as well as specific inhibitors of Interleukin-6 and 
Stat3 amongst other targets (19-23).  A significant challenge is the evaluation of their 
therapeutic effectiveness as they are often cytostatic rather than cytotoxic and changes in tumor 
size occur late if at all. It is recognised that anti-angiogenic agents may therefore result in stable 
disease according to RECIST or PERSIST criteria although tumour necrosis may be seen 
following treatment.  The data from the current study may contribute to support robust metabolic 
response criteria in the absence of change in tumor size when targeted therapy is being used.  
 
Biomarkers that predict whether a drug will lengthen progression free survival (PFS) or overall 
survival (OS) are therefore needed, both for optimising the clinical management of patients and 
to accelerate decisions concerning novel drug efficacy in clinical trials. Bi-dimensional (WHO) or 
uni-dimensional (RECIST) measurements have been used for many years to monitor objective 
response to chemotherapy but certain limitations are recognised: 1. measurable changes take 
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time to allow for tumor shrinkage; 2. in some cases, clinical response to chemotherapy does not 
result in a change in tumor dimensions; 3. tumor response measured by RECIST does not 
always correlate well with PFS or OS (4;6;8;24). In addition, measuring the tumor dimension 
might be an effective criterion in the setting of spherical tumors that change size in a uniform 
fashion following therapy; however, tumor morphologies that do not manifest in this idealized 
shape can be challenging to evaluate for changes in size using uni-dimensional line lengths.  
An important strength of our study is that we fully utilized the capability of FDG-PET/CT by 
performing a CECT after completion of the PET data acquisition. No such CECT repeatability 
study has previously been performed in ovarian cancer patients. Changes in tumor size are 
generally believed to occur at later time points after start of treatment as compared to metabolic 
changes. Tumor size measurements can be affected by partial volume artefacts particularly 
when the target lesion is small when using a CT slice thickness of 5mm and in addition, some 
bowel movement can occur during the time of CT acquisition further compounding partial 
volume artefacts. However, we found a test retest variation as low as 8.8% for tumor diameter 
when measured sequentially. We also assessed changes in tumor volume and found a test 
retest variation of 28.1%; despite this wider variation between repeat measurements in volume, 
changes in tumor volume following treatment may be more sensitive than changes in diameter 
and establishing the repeatability coefficient is thus highly relevant. It is important to point out 
that defining a tumor volume in the abdomen is particularly difficult and automated software 
algorithms for that purpose are currently under investigation. Such algorithms which render 
volumetric and tissue density measurements have been successfully used in the lungs: a study 
demonstrated that a semi-automated algorithm was able to accurately segment 14 out of 15 
patient tumors imaged in thin section CT scans (7;25).  Follow-up CT at 3 weeks after start of 
gefitinib showed that 73% of patients had an absolute change in tumor volume of at least 20%; 
in contrast, only 7% and 27% of patients showed similar changes in their tumor sizes using 
either uni-dimensional or bi-dimensional measurements, respectively.  
An important strength, but also a potential weakness of our study is the highly standardized 
imaging environment with strong academic support. Highly experienced PET and CT reader 
have jointly interpreted the images, which might at least have partially contributed to the 
superiority of tumor size measurements over semi- automated volume measurements. 
Nevertheless, our data also demonstrate that a company based image analysis (CRO read) 
produced results comparable to the site reads. Our approach in this regard is novel as it directly 
allowed a comparison between an academic and a commercial setting for image analysis.  
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The FDG uptake measurements are affected by numerous factors and a meticulous quality 
assurance program needs to be place in order to achieve repeatable PET measurements. This 
includes patient preparation, obtaining blood glucose levels, measuring precisely the amount of 
injected FDG activity as well as scanner calibration amongst others. Of note, a recent study 
found much greater variance of SUV uptake measurements in a clinical PET setting when 
compared to ideal study settings (26). The variation in FDG uptake time is an important 
limitation in the repeatability of FDG-PET and specific efforts need to be place to ensure timely 
procedures. It is of crucial importance for oncologists to work closely together with their imaging 
group to ensure that procedures are in place to enable PET treatment monitoring studies.   
A limitation of our study is that we did not independently repeat each of the two reading 
methods by a further reader, but rather we compared two independent reading methods. 
However, we have attempted to recreate the method used in standard trial sequential reporting 
to closely reflect clinical practice.  Also, the selection of target lesions on the CECT was aided 
by simultaneous viewing of the PET images which could have resulted in an increase in the 
detection of lesions on CT.  
CONCLUSION: 
We have shown excellent test/retest repeatability for FDG-PET/CT quantitative measurements 
in recurrent ovarian cancer across two independent reading methods. The repeatability 
coefficients suggest that a decrease in FDG uptake (SUV) of 15-20% from baseline and 
decrease in tumor size between 10-15% could be used to determine early tumor response. 
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Legends for all figures (Figures 1 to 4) 
 
Left side (a,c) on original scale and Right side (b,d) on log scale. Top (a, b): Scan 1 
value versus Scan 2 value. The paired values from the same subject are plotted against 
each other (the first observation on the y-axis and the second on the x-axis). If the 
paired values from the same subject are similar, the points will fall near the solid line. 
Bottom (c,d): Difference versus Average. The differences and means between the 
paired values are plotted to see if a trend exists. Horizontal lines: dashed lines=mean 
difference, dotted lines=lower and upper 95% confidence limits for difference. 
 
Figure 1. Repeatability of SUVmean at Baseline (Site read) 
Figure 2. Repeatability of SUVmax at Baseline (Site read) 
Figure 3. Repeatability of Tumor (lesion longest) Diameter (mm) at Baseline (Site read) 
Figure 4. Repeatability of Tumor Volume (cc) at Baseline (CRO read) 
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Figure 1. Repeatability of SUVmean at Baseline (Site read) 
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Figure 2. Repeatability of SUVmax at Baseline (Site read) 
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Figure 3. Repeatability of Tumor (lesion longest) Diameter (mm) at Baseline  (Site read) 
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Figure 4. Repeatability of Tumor Volume (cc) at Baseline  (CRO read) 
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Table 1.  Number of target lesions (Site and CRO reads) 
 Site Read 
Combined PET and 
CT target lesions 
CRO Read 
PET target 
lesions 
CRO Read 
CT target lesions 
 Number of patients       21  21            21           
 Mean number of 
target lesions              
4.0  4.4           3.8          
 SD                                1.3  2.4           2.2          
 Median                         5.0  5.0           3.0          
 Range                           (2, 5)  (1, 8)        (1, 8)       
 Total target lesions       85  93            80           
Lesion numbers per 
patient 
   
 1 lesion                         0  2 (9.5%)      3 (14.3%)    
 2 lesions                       4 (19.0%)  5 (23.8%)     5 (23.8%)    
 3 lesions                       4 (19.0%)  2 (9.5%)      3 (14.3%)    
 4 lesions                       0  1 (4.8%)     0 
 5 lesions                       13 (61.9%)  4 (19.0%)     6 (28.6%)    
 6 lesions                       0  1 (4.8%)      1 (4.8%)     
 7 lesions                       0  3 (14.3%)     2 (9.5%)     
 8 lesions                       0  3 (14.3%)     1 (4.8%)     
 
 
 
Table 2. Repeatability of FDG SUV and Tumor Size Measures at Baseline 
PET and CT n CCC and 80% 
CI†  
Geo. 
Mean‡ 
Geo. SD and 
80% CI§  
Geo. CV and 
80% CI* 
Repeatability 
Cut-off¶ % 
Decrease 
 Site Read, up to 5 target lesions                   
 SUV mean (avg)        21  0.95 (0.92,0.98)   6.66  1.07 (1.06,1.08)   6.6 (5.5,8.5)      16.3 
 SUV max (avg)           21  0.94 (0.90,0.97)   9.69  1.07 (1.06,1.09)   7.1 (5.9,9.1)      17.3 
 TD (mm) (avg)            20  0.99 (0.98,1.00)   31.6  1.03 (1.03,1.04)   3.4 (2.8,4.3)       8.8 
 CRO Read, up to 10 target lesions                   
 SUV mwa                   21  0.98 (0.97,0.99)   4.97  1.06 (1.05,1.08)   6.3 (5.3,8.1)      15.6 
 SUV max (avg)           21  0.98 (0.96,0.99)   7.85  1.07 (1.06,1.09)   7.2 (6.0,9.2)      17.6 
 TD (mm) (avg)            20  0.97 (0.95,0.99)   27.7  1.06 (1.05,1.08)   6.0 (5.0,7.7)      14.8 
 
 TV (cc) (avg)              20  0.99 (0.98,1.00)   7.77  1.13 (1.10,1.16)   12.7 (10.5,16.4)   28.1 
 † Concordance correlation coefficient and 80% confidence interval 
 ‡ Geometric grand mean 
 § Geometric within-patient standard deviation and 80% confidence interval 
 *  Geometric within-patient coefficient of variation and 80% confidence interval 
 ¶  Repeatability Cut-off = the lower limit of the 95% CI for % change between two baseline scans 
  TD: tumor diameter; TV: tumor volume; avg: average 
 
 
